Medication Persistence to Lipid-lowering Agents As A Cost-saving Opportunities on Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention in Indonesia
Abstract
Medication persistence is known to reduce acute coronary syndrome (ACS) disease mortality. As much as 13% of Indonesia's budget on national health insurance programs was used for cardiovascular disease. The number of population-based studies discussing the cost-saving opportunities of medication persistence in ACS patients undergoing percutaneous coronary syndrome (PCI) is still minimal. This study aimed to investigate the estimated cost saving of persistence to lipid-lowering agents in patients with ACS after their first PCI. Hospital-based, retrospective cohort study with 2 years of follow-up was conducted with 367 patients. Patients were deemed as having medication persistence if the gap between prescriptions was ≤ 30 days. Persistence assessment was done for lipid-modifying agents (WHO ATC Code: C10). The main outcome is cost-saving opportunities assessed by dividing the difference in total costs resulting from medication persistence with the difference in the proportion of major adverse cardiovascular events (MACE) and major adverse cardiovascular and cerebrovascular events (MACCE) prevented by medication persistence. The study found that direct medical costs incurred by persistent patients were significantly lower than non-persistent patients with lipid-lowering agents (IDR 9,535,209.76 versus IDR 15,933,959.28). Persistence to lipid-lowering therapy can prevent one MACE incident with cost-saving of IDR 996,192.41 when compared to non-persistence patients, while one MACCE incident can be prevented with cost-saving of IDR 733,103.02. Our study indicates that among ACS patients who underwent their first PCI, medication persistence with lipid-lowering agents can contribute to cost-saving in preventing one MACE or MACCE event. These data will be useful for policymakers to help budget allocation and reemphasize the important role of medication persistence with lipid-lowering therapy in the management of ACS after PCI.
References
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., Zieman, S. J., Anderson, J. L., Halperin, J. L., … Yancy, C. W. (2014). 2014 AHA/ACC Guideline for the management of patients with non-st-elevation acute coronary syndromes: Executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines. In Circulation (Vol. 130, Issue 25). https://doi.org/10.1161/CIR.0000000000000133
Anderson, J. L. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 127(4), 362–425. https://doi.org/10.1161/CIR.0b013e3182742cf6
BPJS Kesehatan. (2020). Executive Summary 2019 Program Management Report and Financial Report (Audited). In Badan Penyelenggara Jaminan Sosial (BPJS) Kesehatan. https://bpjs-kesehatan.go.id/bpjs//unduh/index/1520
Chaplin, S., Scuffham, P., Aion, M., & van den, G. B. (2004). Secondary Prevention After Pci: the Cost-Effectiveness of Fluvastatin Therapy in the Netherlands. Value in Health, 7(6), 688–689. https://doi.org/10.1016/s1098-3015(10)65794-4
Claessen, B. E., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N., & Mehran, R. (2020). Lipid management in patients presenting with acute coronary syndromes: A review. Journal of the American Heart Association, 9(24), 1–15. https://doi.org/10.1161/JAHA.120.018897
Fassa, A., Urban, P., Radovanovic, D., Eberli, F., Polikar, R., & Stauffer, J. (2010). Impact of comorbidities on clinical presentation, management and outcome of patients with acute coronary syndrome. Cardiovascular Medicine, 13(05), 155–161. https://doi.org/10.4414/cvm.2010.01502
Kiss, Z., Nagy, L., Reiber, I., Paragh, G., Molnar, M. P., Rokszin, G., Abonyi-Toth, Z., & Mark, L. (2013). Persistence with statin therapy in Hungary. Archives of Medical Science, 9(3), 409–417. https://doi.org/10.5114/aoms.2013.35327
Lin, F. J., Shyu, K. G., Hsieh, I. C., Huey-Herng Sheu, W., Tu, S. Te, Yeh, S. J., Chen, C. I., Lu, K. C., Wu, C. C., Shau, W. Y., Inocencio, T. J., Wen, Y. C., & Yeh, H. I. (2020). Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan. Journal of the Formosan Medical Association, 119(5), 907–916. https://doi.org/10.1016/j.jfma.2020.01.010
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., … Patel, R. S. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
Mihaylova, B., Briggs, A., Hlatky, M., Armitage, J., Parish, S., Gray, A., Collins, R., Collins, R., Meade, T., Sleight, P., Armitage, J., Parish, S., Peto, R., Youngman, L., Buxton, M., De Bono, D., George, C., Fuller, J., Keech, A., … Yeung, M. (2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes, 2(2), 65–72. https://doi.org/10.1161/CIRCOUTCOMES.108.808469
Ministry of Health of Indonesia. (2018). Basic Health Research (RISKESDAS) 2018. In Badan Penelitian dan Pengembangan Kesehatan (p. 198). http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf
Navar, A. M., Roe, M. T., White, J. A., Cannon, C. P., Lokhnygina, Y., Newby, L. K., Giugliano, R. P., Tershakovec, A. M., Braunwald, E., Califf, R. M., & Blazing, M. A. (2019). Medication Discontinuation in the IMPROVE-IT Trial. Circulation. Cardiovascular Quality and Outcomes, 12(1), e005041. https://doi.org/10.1161/CIRCOUTCOMES.118.005041
PERKI. (2018). Pedoman Tata Laksana Sindrom Koroner Akut 2018. In Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
Pittman, D. G., Chen, W., Bowlin, S. J., & Foody, J. M. (2011). Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. American Journal of Cardiology, 107(11), 1662–1666. https://doi.org/10.1016/j.amjcard.2011.01.052
The Central Bureau of Statistics Indonesia. (2021). Pertumbuhan Ekonomi Indonesia Triwulan IV-2020. Www.Bps.Go.Id, 13, 12. https://www.bps.go.id/pressrelease/2021/02/05/1811/ekonomi-indonesia-2020-turun-sebesar-2-07-persen--c-to-c-.html
Trueman, P., Lowson, K., Blighe, A., & Meszaros, A. (2011). Evaluation of the Scale , Causes and Costs of Waste Medicines Evaluation of the Scale , Causes and Costs of Waste Medicines. York Health Economics Consortium, 17, 327–349. http://evi.sagepub.com/cgi/doi/10.1177/1356389011421697
Wake, M., Oh, A., Onishi, Y., Guelfucci, F., Shimasaki, Y., & Teramoto, T. (2019). Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Atherosclerosis, 282(December 2018), 19–28. https://doi.org/10.1016/j.atherosclerosis.2018.12.026
Wei, L., Wang, J., Thompson, P., Wong, S., Struthers, A. D., & MacDonald, T. M. (2002). Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart, 88(3), 229–233. https://doi.org/10.1136/heart.88.3.229
